Merck KGaA, Darmstadt, Germany
Frankfurter Straße 250
Darmstadt
64293
Germany
Tel: 49-6151-720
Fax: 49-6151-722000
Website: https://www.emdgroup.com/en
Email: service@emdgroup.com
428 articles with Merck KGaA, Darmstadt, Germany
-
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
2/16/2019
Merck KGaA, Darmstadt, Germany announced the publication of results from an interim analysis of the pivotal JAVELIN Renal 101 trial online in the New England Journal of Medicine.
-
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
2/11/2019
EMD Serono announced that the US Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for BAVENCIO® in combination with INLYTA®* for patients with advanced renal cell carcinoma.
-
Investments from Merck KGaA, Beacon Pharmaceuticals and Genomenon will provide new jobs for local economies.
-
Across the globe, pharma companies are making an impact. Last week BioSpace launched the first of a weekly roundup of international biotech and pharma news. Here's the latest edition.
-
Merck KGaA, Darmstadt, Germany to Expand US Biopharmaceutical R&D Facility to Advance Innovative ...
2/6/2019
Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Billerica, Massachusetts. -
Merck KGaA, Darmstadt, Germany and GlaxoSmithKline forged an agreement to develop an immunotherapy for difficult to treat cancers that could be worth up to $4 billion. Following the announcement, a subsidiary of Merck KGaA announced plans to expand its Billerica, Mass. R&D facility.
-
GlaxoSmithKline has been in the midst of a significant reshaping to focus on pharmaceuticals, particularly a renewed interest in oncology treatments. As a result, the company has made some cuts to its pipeline, including six quietly announced this morning in the company’s year-end report.
-
Merck KGaA, Darmstadt, Germany and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers
2/5/2019
Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers
-
Elizabeth Varki Jobes, Esq. Joins EMD Serono as Chief Compliance Officer North America
2/4/2019
She will serve as a member of EMD Serono's leadership team, as well as a member of the Global Compliance Healthcare team led by Betania Glorio, Global Compliance Officer, Healthcare, Merck KGaA, Darmstadt, Germany.
-
For Life Science Companies in the Bay State, Project Onramp Opens up Internship Opportunities
1/29/2019
The Massachusetts Biotechnology Council (MassBio) is taking the lead in fostering the next generation of life science leaders in the Bay State with Project Onramp, an internship program that matches talented students from low-income backgrounds with paid internships in the state’s vibrant life sc... -
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
1/24/2019
Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas
-
MilliporeSigma Wins Life Science Industry Award® for Best Use of Social Media
1/15/2019
MilliporeSigma today announced that it has been recognized by BioInformatics LLCwith a 2018 Life Science Industry Award® for best use of social media.
-
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
12/21/2018
Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study's initial hypothesis, and therefore the alliance made the decision to terminate the trial in alignment with the independent Data Monitoring Committee.
-
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
12/20/2018
Agreement enables Merck KGaA, Darmstadt, Germany, to maintain an investment in the rapidly advancing oncology field of CAR-T, while focusing its R&D efforts
-
Intrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen's Vision for Full Developmental Autonomy of its CAR-T Program
12/20/2018
Merck KGaA, Darmstadt, Germany, to assign its Chimeric Antigen Receptor T-cell (CAR-T) rights to Intrexon
-
Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
12/10/2018
Merck KGaA, Darmstadt, Germany, a leading science and technology company, which operates its healthcare business in the U.S. and Canada as EMD Serono, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to M7824, the first regulatory designation for the bifunctional immunotherapy, for the treatment of biliary tract cancer (BTC).
-
Merck KGaA, Darmstadt, Germany, in Agreement with Cyclica for AI-augmented Screening Platform to Expand Research Capabilities
12/6/2018
Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics
-
P&G Completes Acquisition of the Consumer Health Business of Merck KGaA, Darmstadt, Germany
11/30/2018
Today, the Procter & Gamble Company (NYSE: PG) announced the successful completion of its acquisition of the Consumer Health business of Merck KGaA, Darmstadt, Germany.
-
MilliporeSigma, a subsidiary of Merck KGaA, Darmstadt, Germany, handed out $30,000 to three graduate students for their research projects.
-
A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries
11/21/2018
There are 7 billion people in the world. Of those, 5 billion have access to life-saving medications, while 2 billion do not. That is a gap that pharmaceutical companies can help close through increased R&D programs, logistical initiatives and the lowering of prices, the Access to Medicine Foundat...